Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
Authors:
Open Access
- 18 December 2024
- journal article
- letter
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-4
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Multiple myelomaNature Reviews Disease Primers, 2024
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world studyBlood Cancer Journal, 2024
- Real-world analysis of teclistamab in 123 RRMM patients from GermanyLeukemia, 2024
- Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trialNature Medicine, 2023
- Infections following bispecific antibodies in myeloma: a systematic review and meta-analysisBlood Advances, 2023
- Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial resultsNature Medicine, 2023
- Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real‐life outcomes of daratumumab treatmentEuropean Journal of Haematology, 2020
- A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trialLeukemia, 2019